SRPT stock forecast, quote, news & analysis
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders... Show more
Why Sarepta Therapeutics (SRPT) Is Down -6% in the Last 30 Days
Key Takeaways
- SRPT stock declined approximately -6% over the past 30 days amid ongoing concerns over Elevidys sales slowdown and regulatory hurdles.
- Over the past quarter, the stock fell around -19%, driven by clinical trial setbacks, patient safety issues, and weaker-than-expected revenue guidance.
- Major factors include Elevidys shipment pauses following patient deaths, trial failures for approved DMD drugs, and analyst downgrades reflecting pipeline risks.
- Recent positive FDA feedback on confirmatory data provided minor support but failed to reverse the downtrend.
- Biotech sector volatility and Sarepta's high beta amplified price movements in a challenging macro environment for gene therapies.
Sarepta Therapeutics (SRPT) Company Overview and Market Position
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare diseases, particularly Duchenne muscular dystrophy (DMD). Its core business model centers on RNA-targeted therapeutics, gene therapies, and siRNA platforms, with key products like EXONDYS 51, VYONDYS 53, AMONDYS 45, and the gene therapy ELEVIDYS targeting specific DMD mutations. Operating in the competitive biotech sector against players like Roche and Novartis, Sarepta holds a leading position in exon-skipping therapies for DMD but faces intense scrutiny on gene therapy safety and efficacy. These fundamentals expose the stock to regulatory and clinical risks, explaining recent price pressure from Elevidys-related setbacks amid a narrowing addressable market.
Sarepta Therapeutics (SRPT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, SRPT stock declined from around $18.80 (late February close) to $17.61 (March 24 close), marking a -6% drop. The movement was volatile and range-bound, dipping to lows near $15.90 in early March before a partial rebound, reflecting choppy trading amid mixed news flow.
For the past quarter, the stock fell sharply from approximately $22.00 (late December) to $17.61, a -19% decrease. This trend-driven downside featured steep declines tied to specific catalysts, with heightened volatility as shares tested 52-week lows around $10.42 earlier in the period.
What Drove SRPT Stock Price in the Last 30 Days
The 30-day downturn stemmed primarily from persistent Elevidys challenges, including suspended shipments to non-ambulatory patients after FDA concerns over three patient deaths linked to acute liver failure. Q4 2025 preliminary results showed Elevidys sales missing estimates at $110 million, blamed on flu season and label restrictions, eroding investor confidence. Early March saw shares hit $15.87 lows amid broader biotech weakness. A brief uptick followed FDA agreement to review ESSENCE Phase 3 data for traditional approvals of AMONDYS 45 and VYONDYS 53, but weak sales outlook capped gains. Analyst actions, including BofA's Underperform reiteration citing regulatory risks, further pressured sentiment.
What Drove SRPT Stock Performance Over the Last Quarter
The quarterly decline was fueled by cascading negative events, starting with July 2025 FDA requests to halt Elevidys shipments and clinical holds after three deaths, triggering a 30-40% plunge and multiple downgrades. November's trial failure in confirmatory studies for two approved DMD drugs, coupled with lowered Elevidys forecasts, caused another 30% drop, highlighting pipeline fragility. Macro factors like biotech sector rotation amid rising rates and inflation squeezed valuations, while institutional selling amplified the slide. Cost-cutting and pipeline refocus offered some stabilization, but cumulative safety and revenue risks dominated, pushing shares toward yearly lows.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from hundreds available on the platform, which trade thousands of tickers across various markets. This curated section highlights bots with the strongest recent performance based on metrics like win rate, profit factor, and risk-adjusted returns. Strategies range from day trading and swing trading to long-term trend following, with timeframes spanning intraday to monthly holds. Each bot includes detailed stats, backtests, and live trading records, helping investors identify relevant tools for stocks like SRPT. Explore the page to discover bots tailored to current market trends and potentially enhance your stock analysis.
SRPT Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor FDA outcomes on supplemental applications for AMONDYS 45 and VYONDYS 53 by late April, including ESSENCE data review. Upcoming EMBARK study updates at ASGCT and ENDEAVOR Cohort 8 enrollment for Elevidys in non-ambulatory patients could sway sentiment. Pipeline progress in siRNA programs like SRP-1001 and SRP-1003, plus LGMD therapies, remains key amid safety scrutiny. Macro trends in biotech funding, interest rates, and regulatory shifts for gene therapies will influence sector flows. Risks include further Elevidys label changes or sales misses, while catalysts like positive AdCom votes or partnerships could drive volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Aroon Indicator for SRPT shows an upward move is likely
SRPT's Aroon Indicator triggered a bullish signal on April 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 186 similar instances where the Aroon Indicator showed a similar pattern. In of the 186 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for SRPT just turned positive on March 09, 2026. Looking at past instances where SRPT's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
SRPT moved above its 50-day moving average on March 25, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SRPT crossed bullishly above the 50-day moving average on March 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SRPT advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for SRPT moved out of overbought territory on March 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 57 cases where SRPT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on April 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SRPT as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRPT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SRPT broke above its upper Bollinger Band on March 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SRPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.950) is normal, around the industry mean (26.162). P/E Ratio (27.205) is within average values for comparable stocks, (45.457). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.767). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (0.965) is also within normal values, averaging (317.372).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of treatments for life-threatening illnesses and viruses
Industry Biotechnology